Maravai LifeSciences Holdings, Inc. (MRVI)
| Market Cap | 1.96B +135.9% |
| Revenue (ttm) | 213.00M +10.7% |
| Net Income | -65.67M |
| EPS | -0.45 |
| Shares Out | 259.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,992,234 |
| Open | 7.73 |
| Previous Close | 7.68 |
| Day's Range | 7.39 - 7.75 |
| 52-Week Range | 2.80 - 9.42 |
| Beta | 0.63 |
| Analysts | Buy |
| Price Target | 9.64 (+27.89%) |
| Earnings Date | Nov 4, 2026 |
About MRVI
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents ... [Read more]
Financial Performance
In 2025, MRVI's revenue was $185.74 million, a decrease of -28.34% compared to the previous year's $259.19 million. Losses were -$130.77 million, -9.72% less than in 2024.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for MRVI stock is "Buy." The 12-month stock price target is $9.64, which is an increase of 27.89% from the latest price.
News
Maravai LifeSciences Holdings Transcript: Stifel 2026 Healthcare Conference 2026
TriLink’s mRNA pipeline is expanding, with over 50 GMP customers and commercial potential of up to $50 million+ per program. Improved visibility, portfolio bundling and a reset cost base support growth and margin ambitions.
KeyBanc upgrades Maravai to Overweight on midterm election results
KeyBanc last night upgraded Maravai Lifesciences (MRVI) to Overweight from Sector Weight with an $11 price target The Trump Administration and Robert F. Kennedy Jr. as Head of Health and…
Maravai Lifesciences upgraded to Overweight from Sector Weight at KeyBanc
KeyBanc analyst Paul Knight upgraded Maravai Lifesciences (MRVI) to Overweight from Sector Weight with an $11 price target
Maravai Lifesciences price target raised to $10 from $7 at Craig-Hallum
Craig-Hallum raised the firm’s price target on Maravai Lifesciences (MRVI) to $10 from $7 and keeps a Buy rating on the shares. The firm notes Q3 results featured a beat/raise…
Maravai Lifesciences price target raised to $9.50 from $8 at Stifel
Stifel analyst Daniel Arias raised the firm’s price target on Maravai Lifesciences (MRVI) to $9.50 from $8 and keeps a Buy rating on the shares.
Maravai LifeSciences Holdings Slides: Investor presentation
Maravai LifeSciences Holdings has posted slides in relation to its latest quarterly earnings report, which was published on November 5, 2026.
Maravai LifeSciences Holdings Earnings Call Transcript: Q3 2026
Q3 revenue grew 10% YoY, with mRNA and Cygnus strength driving improved adjusted profitability. 2026 revenue and adjusted EBITDA guidance increased, while GMP and CDMO timing remains lumpy and 2027 GMP activity is expected to skew to H2.
Maravai LifeSciences Holdings Earnings release: Q3 2026
Maravai LifeSciences Holdings released its Q3 2026 earnings on November 4, 2026, summarizing the period's financial results.
Maravai LifeSciences Holdings Slides: Q3 2026
Maravai LifeSciences Holdings has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 4, 2026.
Maravai LifeSciences Holdings Quarterly report: Q3 2026
Maravai LifeSciences Holdings has published its Q3 2026 quarterly earnings report on November 4, 2026.
Maravai Lifesciences reports Q3 EPS (9c), consensus (6c)
Reports Q3 revenue $45.9M, consensus $43.6M. “Our third-quarter results build on the momentum we established in the first half of the year,” said Bernd Brust, CEO of Maravai LifeSciences (MRVI).
Maravai LifeSciences Reports Third Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported ...
Maravai LifeSciences Announces November 2026 Investor Conference Schedule
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the...
Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its th...
Maravai Lifesciences initiated with a Buy at TD Cowen
TD Cowen initiated coverage of Maravai Lifesciences (MRVI) with a Buy rating and $9 price target The company’s core CleanCap revenue growth is returning, but its larger, more undervalued opportunity…
TriLink BioTechnologies® Secures Additional China Patent for CleanCap® Technology, Adding Broad Composition-of-Matter Protection to Reinforce Its Global IP
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies, LLC (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, today announced it has bee...
Maravai LifeSciences Holdings Slides: Investor presentation
Maravai LifeSciences Holdings has posted slides in relation to its latest quarterly earnings report, which was published on September 25, 2026.
Maravai Lifesciences initiated with a Neutral at UBS
UBS analyst Doug Schenkel initiated coverage of Maravai Lifesciences (MRVI) with a Neutral rating and $8 price target The firm initiated and resumed 25 life science and diagnostics tools companies.
Stifel sees Moderna data as positive for Repligen, Maravai
Stifel views Moderna’s (MRNA) Phase 3 INTerpath-001 data as good for Repligen (RGEN) and “conceptually good” for Maravai Lifesciences (MRVI). Repligen called out specific involvement in Moderna and Me...
Maravai LifeSciences Holdings Earnings Call Transcript: Q2 2026
Q2 2026 saw 9% revenue growth, margin expansion, and strong execution across both segments. TriLink's GMP consumables and discovery mRNA drove results, while Cygnus maintained steady growth. Guidance remains prudent due to variability in large orders, but profitability and liquidity have improved.
Maravai LifeSciences Holdings Earnings release: Q2 2026
Maravai LifeSciences Holdings released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Maravai LifeSciences Holdings Slides: Q2 2026
Maravai LifeSciences Holdings has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 6, 2026.
Maravai LifeSciences Holdings Quarterly report: Q2 2026
Maravai LifeSciences Holdings has published its Q2 2026 quarterly earnings report on August 6, 2026.
Maravai LifeSciences Reports Second Quarter 2026 Financial Results
SAN DIEGO--(BUSINESS WIRE)--Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported ...
Maravai LifeSciences Holdings Slides: Investor presentation
Maravai LifeSciences Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.